NYSE: NVO - Novo Nordisk A/S

Yield per half year: -34.34%
Sector: Healthcare

Share chart Novo Nordisk A/S


About

Novo Nordisk A/S, медицинская компания, занимается исследованиями, разработками, производством и маркетингом фармацевтической продукции по всему миру. Он работает в двух сегментах: лечение диабета и ожирения и биофармация. Сегмент лечения диабета и ожирения предоставляет продукты в области инсулинов, GLP-1 и родственных систем доставки, пероральных противодиабетических продуктов, ожирения и других хронических заболеваний. Сегмент биофармацевтических препаратов предлагает продукты для лечения гемофилии, нарушений роста и заместительной гормональной терапии.

More details
Соглашения о сотрудничестве компании с Gilead Sciences, Inc. Novo Nordisk A/S также сотрудничает в исследованиях с Lumen Bioscience, Inc. для изучения стратегий доставки пероральных биопрепаратов для лечения кардиометаболических заболеваний. Компания была основана в 1923 году и имеет штаб-квартиру в Багсверде, Дания.


Main settings

Сайт https://www.novonordisk.com
P/E 23.29
P/S 7.44
P/BV 15.75
EV/EBITDA 15.51
EBITDA 57.79
Цена ао 123.45
Дивиденд ао 1.76
Див.доход ао 0.96
Выручка 122.02
ISIN US6701002056
Число акций ао 4.4948 млрд
Change price per day: +0.0324% (123.45)
Change price per week: +1.6797% (121.45)
Change price per month: +14.32% (108.02)
Change price per 3 month: +21.75% (101.43)
Change price per half year: -34.34% (188.07)
Change price per year: -13.99% (143.57)
Change price per 3 year: +78.4% (69.22)
Change price per year to date: +19.35% (103.47)


All parameters ⇨

Grade

Underestimation

Title Value Grade
P/S 7.44 1
P/BV 15.75 1
P/E 23.29 5
EV/EBITDA 15.51 4
Total:

Efficiency

Title Value Grade
ROA, % 30.12 9
ROE, % 88.07 10
Total:

Dividends

Title Value Grade
Div yield, % 0.7329 1
DSI 0.86 9
Total:

Debt

Title Value Grade
Debt/EBITDA 0.239 10
Total:

Growth impulse

Title Value Grade
Profit growth, % 44.43 9
Share price growth, % 62.15 10
Dividend growth, % 20.71 4
Total:

Dividends

Dividends, % Dividends Result of period Buy before Register closing date Payment before
0.59% 0.85 IV кв. 2022 22.03.2023 24.03.2023 10.04.2023

Main owners

Institutions Volume Share, %
Jennison Associates LLC 22527772 0.66
Renaissance Technologies, LLC 16229476 0.47
Fisher Asset Management, LLC 14193693 0.41
Bank of America Corporation 12781305 0.37
FMR, LLC 12077501 0.35
Sarofim, Fayez & Co 11603964 0.34
Morgan Stanley 9215098 0.27
Loomis Sayles & Company, LP 9097808 0.26
Folketrygdfondet 8631264 0.25
Price (T.Rowe) Associates Inc 8230915 0.24

Contained in ETF

Similar companies



Company management

Head Job title Payment Year of birth
Mr. Lars Fruergaard Jorgensen President, CEO & Member of Management Board 4.72M 1966 (58 years)
Mr. Karsten Munk Knudsen Executive VP, CFO & Member of the Management Board 1.87M 1971 (53 years)
Mr. Henrik Ehlers Wulff Executive VP of Product Supply, Quality & IT and Member of the Management Board 1.88M 1970 (54 years)
Ms. Camilla Sylvest Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board 1.84M 1972 (52 years)
Mr. Maziar Mike Doustdar Executive VP of International Operations & Member of the Management Board N/A 1970 (54 years)
Mr. Douglas J. Langa Executive VP of North America Operations & Member of Management Board N/A 1966 (58 years)
Mr. Ludovic Helfgott Executive VP, Head of Rare Disease & Member of Management Board N/A 1974 (50 years)
Dr. Martin Holst Lange Executive VP of Development & Member of the Management Board 1.78M 1970 (54 years)
Dr. Marcus Schindler Ph.D. EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board 1.78M 1966 (58 years)
Ms. Tania Sabroe Executive VP of Global People & Organisation and Member of Management Board N/A

About company

Address: Denmark, Bagsvaerd, Novo Allé 1 - open in Google maps, open in Yandex maps
Website: https://www.novonordisk.com
Phone: +tel:4544448888